此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

2026年11月8日 更新者:Nuvation Bio Inc.

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review [BICR] per modified Response Assessment in Neuro-Oncology [RANO] 2.0), and are not in need of immediate chemotherapy or radiotherapy.

研究概览

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Los Angeles、California、美国、90095
        • 尚未招聘
        • University of California, Los Angeles
        • 首席研究员:
          • Robert Chong, MD
        • 接触:
      • San Francisco、California、美国、94143
        • 尚未招聘
        • University of California, San Francisco
        • 首席研究员:
          • John De Groot, MD
        • 接触:
    • Connecticut
      • New Haven、Connecticut、美国、06510
    • Florida
      • Miami、Florida、美国、33136
        • 尚未招聘
        • University of Miami Health
        • 接触:
        • 首席研究员:
          • Juan Blaquier, MD
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • 招聘中
        • Indiana University
        • 首席研究员:
          • Kathryn Nevel, MD
        • 接触:
          • NeuroOncology Clinical Trials
          • 电话号码:3179634823
          • 邮箱:neuroct@iu.edu
    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • 尚未招聘
        • LSU LCMC Health Cancer Center
        • 首席研究员:
          • Yazmin Odia, MD
        • 接触:
    • Massachusetts
      • Boston、Massachusetts、美国、02214
        • 尚未招聘
        • Massachusetts General Hospital
        • 接触:
        • 首席研究员:
          • Vihang Nakhate, MD
    • New Jersey
      • New Brunswick、New Jersey、美国、08901
        • 尚未招聘
        • Rutgers Cancer Institute
        • 首席研究员:
          • Morana Vojnic, MD
        • 接触:
    • New York
      • New York、New York、美国、10016
      • New York、New York、美国、10032
        • 尚未招聘
        • Columbia University Medical Center
        • 首席研究员:
          • Andrew Lassman, MD
        • 接触:
    • Ohio
      • Cleveland、Ohio、美国、44106
        • 尚未招聘
        • Cleveland Clinic
        • 首席研究员:
          • Mina Lobbous, MD
        • 接触:
      • Columbus、Ohio、美国、43210
        • 尚未招聘
        • The Ohio State University Comprehensive Cancer Center
        • 接触:
        • 首席研究员:
          • Pierre Giglio, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
  • IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
  • Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
  • Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
  • Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
  • Adequate hematologic and organ function
  • Expected survival of ≥12 months

Key Exclusion Criteria:

  • Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
  • Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
  • Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
  • Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
  • Significant functional or neurocognitive deficits, including uncontrolled seizures
  • Evidence of leptomeningeal disease.
  • Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Safusidenib

Safusidenib 250 mg BID

Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

次要结果测量

结果测量
措施说明
大体时间
ORR per modified RANO 2.0 assessed by Investigator
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

ORR defined as the proportion of participants with the confirmed best overall response of CR, PR or MR per modified RANO 2.0, assessed by the Investigator

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
Volumetric Tumor Growth Rate (TGR) by BICR
大体时间:From historical scans through the final scan in the study, approximately 18 months

TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR

From historical scans through the final scan in the study, approximately 18 months
Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

DOR, time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier.

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
Time to Next Intervention (TTNI)
大体时间:From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months

TTNI, defined as the time from the first dose of study drug to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier

From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

PFS, defined as the time from the first dose of study drug to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier.

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator
大体时间:From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months

TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0, assessed by BICR and by the Investigator

From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
Overall Survival (OS)
大体时间:From the date of first dose of study drug until the date of death, approximately 18 months

OS, defined as the time from the first dose of study drug to death from any cause.

From the date of first dose of study drug until the date of death, approximately 18 months
Safety and tolerability
大体时间:From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months

The safety and tolerability of safusidenib evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs

From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
Seizure Activity
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年3月1日

初级完成 (估计的)

2030年9月1日

研究完成 (估计的)

2032年3月1日

研究注册日期

首次提交

2026年7月9日

首先提交符合 QC 标准的

2026年7月9日

首次发布 (实际的)

2026年7月14日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月8日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅